We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Bristol Myers Squibb (BMS) unveiled positive interim results from its phase 3 CheckMate trial, showing that Opdivo (nivolumab) plus chemotherapy significantly improved event-free survival in patients with resectable IB-IIIA nonsmall-cell lung cancer (NSCLC). Read More
GlaxoSmithKline’s (GSK) daprodustat increased or maintained hemoglobin levels in patients with anemia due to chronic kidney disease (CKD) across five phase 3 studies, says a new analysis. Read More
Both treatments remove white blood cells from the patients, genetically modify them to recognize the patient’s individual tumor and then reinfuse the bespoke CAR-T treatment. Read More
Pfizer’s investigational antiviral, Paxlovid (07321332 plus ritonavir) cut the risk of COVID-19 associated hospitalizations and death by 89 percent compared to placebo in an interim analysis of a phase 2/3 study, the company announced Friday. Read More
Two CAR-T treatments — one from Gilead Sciences and another from Bristol Myers Squibb (BMS) — trounced standard-of-care as second-line therapies for patients with relapsed or refractory large B-cell lymphomas in two late-stage studies. Read More
Cortexyme isn’t letting a missed primary endpoint stifle its conviction that P. gingivalis, the bacteria that causes periodontal disease, is a root cause of Alzheimer’s disease (AD) and that its oral medication atuzaginstat can put the brakes on both cognitive and functional degeneration. Read More
In the study of 52,998 healthcare employees, just 11.6 percent of people with a history of severe allergic reactions reported an allergic reaction after getting a COVID-19 mRNA vaccine. Read More
The FDA has teamed up with the National Institutes of Health (NIH), 10 pharmaceutical companies and five nonprofit organizations to launch the Bespoke Gene Therapy Consortium to accelerate development of gene therapies for rare diseases. Read More
A 10-day course of the inexpensive antidepressant fluvoaxamine cut the risk of COVID-19-related hospitalization by 32 percent in infected patients with comorbidities, a research team in Brazil has found. Read More